Avid Bioservices Inc (CDMO)

[goodJohnhunting]

Sulaco, RE: "CP, here's a post of mine from 5/14/2013"

Below is a post of mine from 1/5/13.. I didn't go back any further, but I believe MrsKatie and I had this discussion back in 2004/05.. Some of which were erased because of TOS violation.. Which btw is crazy..

3) anionic charge of PS is effected in the tumor microenvironment, allowing for receptive binding of protein and Bavituximab. Not so with programmed cell death (my theory)

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=83098930&txt2find=binding|theory

CP more eloquently stated in his response to you earlier (the loss of "charge" in tumor cells because of loss of motion?), as motion is required for electrostatic/electromagnetic charge.

My quote above is exactly what he is eluding too.

However, I'm also referencing that PD1 in not "cross reactive", and is not dependent upon "charge" in relation to tumor expression.

From your post today:

With PS externalization, M1 macrophages are depolarized to M2 macrophages, and electromagnetic changes in the membrane place the cell outside the reach of the immune system. In a sense, the cell loses its "magnetism." The immune system cannot thus "dock" onto the cell membrane and protect it.

I've theorized that when cellular necrosis occurs there is a loss of molecular ionic bonding. What effect would this have on protein binding factors for Bavituximab? (B2GP1 2tonelephant)

Inflammation destroys magnetism. Stress, smoking, poor diet, age, lack of exercise...all destroy magnetism.

If this is true in regards to electrostatic charge, then wouldn't this provide credence to my "Unstable", "Unpredictable", and "Unknown Variances" theory in relation to B2gp1 levels?

All the best,
John